Solodyn - Treating Acne with Solodyn
Links shared publicly online about this topic.
- 1,210total visits
Solodyn - Treating Acne with Solodyn
View full resource at acne.about.com
Most Recently Shared on April 27, 2010 at 10:10 am By:
Solodyn: Solodyn is an extended release minocycline used to treat acne. Is Solodyn… http://goo.gl/fb/ehcTs #acne
Drug Induced Lupus Connected with Acne Fighting Solodyn's Minocycline | InjuryBoard Atlanta
atlanta.injuryboard.com — “Drug Induced Lupus Connected with Acne Fighting Solodyn's Minocycline | InjuryBoard Atlanta” View full resource at atlanta.injuryboard.com
Most Recently Shared on November 16, 2011 at 5:18 pm By:
Drug Induced Lupus Connected with Acne Fighting Solodyn's Minocycline: Millions of Americans turn to acne-fighti... http://t.co/ofBEFAIb
How Quickly Should Bactrim DS Stop Cystic Acne? Doctor Answers, Tips
realself.com — “Several tetracyclines have failed ( doxy, mino, solodyn) as have topicals (evoclin, triaz, duac, retin-a, aczone. I started Bactrim DS 3 weeks ago (2x...” View full resource at realself.com
Most Recently Shared on May 21, 2011 at 12:32 pm By:
Allergic Reaction To Solodyn (Newest posts first) - The People's Medicine Community
prescriptiondrug-info.com — “My son suffered an allergic reaction to solodyn He was prescribed for acne He was on the medication for 1 month with no reaction Was then put on a different antibotic for one month and then switched back to Solodyn After three days on the Solodyn he broke out in a rash Large bumps most in big cluste (Newest posts first)” View full resource at prescriptiondrug-info.com
Most Recently Shared on December 31, 2010 at 8:35 pm By:
" I think i am also allergic to this medication. I broke out in hives throughout my body, drank a lot of wate http://PD0.US/F192993
USPTO awards Medicis new patent for SOLODYN Extended Release Tablets
news-medical.net — “Medicis today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 7,790,705 related to the use of SOLODYN® (minocycline HCI, USP) Extended Release Tablets. The new patent, entitled "Minocycline Oral Dosage Forms for the Treatment of Acne," relates to the use of dosage forms of SOLODYN which provide approximately 1 mg/kg dosing based on the body weight of the person, and expires in 2027.” View full resource at news-medical.net
Most Recently Shared on September 8, 2010 at 1:11 pm By:
Pregnancy News: USPTO awards Medicis new patent for SOLODYN Extended Release Tablets: Medicis today announced that... http://bit.ly/bT0mUC
Three Additional Strengths of Solodyn Approved
acne.about.com — “Three Additional Strengths of Solodyn Approved” View full resource at acne.about.com
Most Recently Shared on September 2, 2010 at 6:47 am By:
Three Additional Strengths of Solodyn Approved: Three additional strengths of the acne… http://goo.gl/fb/egaJ4 #acne
FDA approves additional strengths of SOLODYN for inflammatory lesions treatment
news-medical.net — “Medicis today announced that the U.S. Food and Drug Administration (FDA) has approved additional strengths of SOLODYN (minocycline HCl, USP) Extended Release Tablets in 55 mg, 80 mg and 105 mg dosages for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older.” View full resource at news-medical.net
Most Recently Shared on August 30, 2010 at 5:35 pm By:
Pregnancy News: FDA approves additional strengths of SOLODYN for inflammatory lesions treatment: Medicis today ann... http://bit.ly/a30UnM
FDA issues quarterly list of drugs under safety investigation - Related Stories - AAP SmartBrief
smartbrief.com — “The FDA released its quarterly list of drugs under review for potential safety issues. Included are Pfizer's cancer treatment Sutent, Wyeth and Progenics Pharmaceuticals' constipation drug Relistor, and Medicis Pharmaceutical's antibiotic Solodyn. The agency reiterated that appearance on the list "d” View full resource at smartbrief.com
Most Recently Shared on October 12, 2009 at 3:09 am By:
FDA issues quarterly list of drugs under safety investigation http://sbne.ws/r/2ZB7
Advertisement

